The use of mesenchymal stem cells of bone marrow in the treatment of patients with acute attack of ulcerative colitis
DOI:
https://doi.org/10.15587/2313-8416.2015.40957Keywords:
biological therapy, inflammatory bowel disease, mesenchymal stem cells, ulcerative colitisAbstract
Aim: to compare the mid-term results of treatment of patients with acute attack of moderate and severe ulcerative colitis receiving standard anti-inflammatory therapy and integrated anti-inflammatory therapy using allogeneic culture of mesenchymal stem cells of bone marrow.
Materials and methods. Patients with acute attack of ulcerative colitis were divided into two groups. The first group of patients with UC (n=12) in addition to standard anti-inflammatory therapy, received the culture of mesenchymal stem cells (MSC). The second group of patients (n=10) received standard anti-inflammatory therapy with 5-aminosalicylic acid (5-ASA) and glucocorticosteroids (GCS). The clinical activity of UC was assessed on a scale D. Rachmilewitz endoscopic picture was assessed on a scale of Mayo. The duration of remission in groups of patients was estimated by the method of Kaplan-Meier.
Results. The original index of Rachmilevitz and the index of Mayo in both groups were comparable. In a year from the start of the study, the risk of recurrence of ulcerative colitis, duration of remission, indices of clinical and endoscopic activity in both groups of patients were comparable. After two years, the effectiveness of anti-inflammatory therapy on major indicators was higher in the group of patients treated with MSC. However, after 3 years of follow-up in both groups clinical and endoscopic indices showed no significant differences.
Conclusion. The introduction of a culture of MSC increases the effectiveness of anti-inflammatory therapy in patients with acute attack of ulcerative colitis, increases the duration of disease remission, reduces to 3 times the risk of attack within 2 years of observation
References
Recommendations for the diagnosis and treatment of adult patients with ulcerative colitis (2013). Proctology, 3 (45), 4–38.
Pershko, A. M., Samedov, B. H., Rukshin, O. A. (2003). Ulcerative colitis: diagnosis and treatment. St. Petersburg, 112.
Sadler, R. S. (1994). Epidemiology of inflammatory bowel disease. Inflammatory bowel disease: From bench to bedside. Baltimore, Williams and Wilkins, 5–30.
Amosy E. M’Koma. Inflammatory Bowel Disease: An Expanding Global Health Problem. Clinical Medicine Insights: Gastroenterology 2013:6 33–47. doi: 10.4137/cgast.s12731
Belousova, E. A., Nikitina, N. V., Tsodikova, O. M. (2013). Treatment of ulcerative colitis mild and moderate flow. Farmateka, 2, 42–46.
Khalif, I. L. (2006). Medical Management of ulcerative colitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology, 16 (3), 58–62.
Khalif, I. L. (2006). Principles of treatment of ulcerative colitis (recommendations of the Russian group to study inflammatory bowel disease). Proctology, 2, 31–33.
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M. et. al. (2012). Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. Journal of Crohn’s and Colitis, 6 (10), 991–1030. doi: 10.1016/j.crohns.2012.09.002
Langholz, E., Munkholm, P., Davidsen, M., Binder, V. (1994). Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology, 107, 3–11.
Michelassi, F., Fichera, A.; Kirshner, J. B. (Еd.) (2000). Inflammatory Bowel Disease. 5-th edition. Philadelphia, 616–626.
Vorobiev, G. I., Khalif, I. L. (2008). Inflammatory bowel disease. Moscow: Miklos, 400.
Knyazev, O. V., Churikova, A. A. (2014). Anticytokine therapy and quality of life in patients with inflammatory bowel disease. Evidence gastroenterology, 2, 17–23.
Farkas, K., Lakatos, P. L., Nagy, F., Szepes, Z., Miheller, P., Papp, M. et. al. (2013). Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scandinavian Journal of Gastroenterology, 48 (12), 1394–1398. doi: 10.3109/00365521.2013.845906
Zhang, Q., Shi, S., Liu, Y., Uyanne, J., Shi, Y., Shi, S., Le, A. D. (2009). Mesenchymal Stem Cells Derived from Human Gingiva Are Capable of Immunomodulatory Functions and Ameliorate Inflammation-Related Tissue Destruction in Experimental Colitis. The Journal of Immunology, 183 (12), 7787–7798. doi: 10.4049/jimmunol.0902318
Knyazev, O. V., Parfenov, A. I., Shcherbakov, P. L., Ruchkina, I. N., Konoplyannikov, A. G. (2013). Cell therapy for refractory Crohn's disease. Cell technologies in biology and medicine, 3, 145–152.
Ciccocioppo, R., Bernardo, M. E., Sgarella, A. et al. (2011). Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut, 60 (6), 788–798. doi: 10.1136/gut.2010.214841
Lalu, M. M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B. W., Marshall, J. C. et. al. (2012). Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials. PLoS ONE, 7 (10), e47559. doi: 10.1371/journal.pone.0047559
Van Deen, W. K., Oikonomopoulos, A., Hommes, D. W. (2013). Stem cell therapy in inflammatory bowel disease. Current Opinion in Gastroenterology, 29 (4), 384–390. doi: 10.1097/mog.0b013e328361f763
Belousova, E. A. (2002). Ulcerative colitis and Crohn's disease. Tver: Triad, 128.
Recommendations for the diagnosis and treatment of adult patients with ulcerative colitis (2013). Proctology, 3 (45), 4–38.
D’Haens, G., Sandborn, W. J., Feagan, B. G., Geboes, K., Hanauer, S. B., Irvine, E. J. (2007). A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis. Gastroenterology, 132 (2), 763–786. doi: 10.1053/j.gastro.2006.12.038
Rachmilewitz, D. (1989). Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ, 298 (6666), 82–86. doi: 10.1136/bmj.298.6666.82
Sadler, R. S. (1994). Epidemiology of inflammatory bowel disease. Inflammatory bowel disease: From bench to bedside. Baltimore, Williams and Wilkins, 5–30.
Tsyb, A. F., Konoplyannikov, A. G., Kolesnikov, A. I. et al. (2004). The preparation and use in medicine cell cultures of mesenchymal stem cells in human bone marrow. Bulletin of the Russian Academy of Medical Sciences, 59 (9), 71–76.
Ferrante, M., Vermeire, S., Katsanos, K. H., Noman, M., Van Assche, G., Schnitzler, F. (2007). Predictors of early response to infliximab in patients with ulcerative colitis. Inflammatory Bowel Diseases, 13 (2), 123–128. doi: 10.1002/ibd.20054
Oyama, Y., Traynor, A. E., Barr, W., Burt, R. K. (2003). Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens. Bone Marrow Transplant, 32, S81–S83. doi: 10.1038/sj.bmt.1703950
Downloads
Published
Issue
Section
License
Copyright (c) 2015 Олег Владимирович Князев, Анна Валерьевна Каграманова, Оксана Николаевна Болдырева, Нина Александровна Фадеева, Елена Юрьевна Жулина, Екатерина Михайловна Мясникова, Петр Леонидович Щербаков, Анатолий Георгиевич Коноплянников, Альбина Александровна Лищинская, Ирина Николаевна Ручкина, Асфольд Иванович Парфенов
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
